nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—CYP3A5—Sorafenib—thyroid cancer	0.0337	0.44	CbGbCtD
Vardenafil—CYP3A4—Vandetanib—thyroid cancer	0.0218	0.285	CbGbCtD
Vardenafil—PDE11A—thyroid gland—thyroid cancer	0.0134	0.133	CbGeAlD
Vardenafil—CYP3A4—Sorafenib—thyroid cancer	0.0132	0.172	CbGbCtD
Vardenafil—PDE6H—head—thyroid cancer	0.0119	0.118	CbGeAlD
Vardenafil—PDE6G—head—thyroid cancer	0.0114	0.113	CbGeAlD
Vardenafil—PDE10A—thyroid gland—thyroid cancer	0.0087	0.0862	CbGeAlD
Vardenafil—PDE1B—thyroid gland—thyroid cancer	0.00862	0.0854	CbGeAlD
Vardenafil—PDE6G—lymph node—thyroid cancer	0.008	0.0793	CbGeAlD
Vardenafil—CYP3A4—Doxorubicin—thyroid cancer	0.00798	0.104	CbGbCtD
Vardenafil—PDE10A—head—thyroid cancer	0.00772	0.0765	CbGeAlD
Vardenafil—PDE1B—head—thyroid cancer	0.00765	0.0758	CbGeAlD
Vardenafil—PDE10A—lymph node—thyroid cancer	0.0054	0.0536	CbGeAlD
Vardenafil—PDE1B—lymph node—thyroid cancer	0.00536	0.0531	CbGeAlD
Vardenafil—PDE5A—thyroid gland—thyroid cancer	0.00509	0.0505	CbGeAlD
Vardenafil—PDE5A—head—thyroid cancer	0.00452	0.0448	CbGeAlD
Vardenafil—PDE5A—lymph node—thyroid cancer	0.00316	0.0313	CbGeAlD
Vardenafil—Paraesthesia—Vandetanib—thyroid cancer	0.00202	0.00394	CcSEcCtD
Vardenafil—Dyspnoea—Vandetanib—thyroid cancer	0.00201	0.00392	CcSEcCtD
Vardenafil—Feeling hot—Epirubicin—thyroid cancer	0.00201	0.00391	CcSEcCtD
Vardenafil—Tinnitus—Sorafenib—thyroid cancer	0.002	0.00389	CcSEcCtD
Vardenafil—Cardiac disorder—Sorafenib—thyroid cancer	0.00199	0.00387	CcSEcCtD
Vardenafil—Flushing—Sorafenib—thyroid cancer	0.00199	0.00387	CcSEcCtD
Vardenafil—Dyspepsia—Vandetanib—thyroid cancer	0.00198	0.00387	CcSEcCtD
Vardenafil—Ventricular arrhythmia—Doxorubicin—thyroid cancer	0.00197	0.00384	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00195	0.00379	CcSEcCtD
Vardenafil—Angiopathy—Sorafenib—thyroid cancer	0.00194	0.00378	CcSEcCtD
Vardenafil—Immune system disorder—Sorafenib—thyroid cancer	0.00193	0.00377	CcSEcCtD
Vardenafil—Mediastinal disorder—Sorafenib—thyroid cancer	0.00193	0.00376	CcSEcCtD
Vardenafil—Pain—Vandetanib—thyroid cancer	0.00193	0.00376	CcSEcCtD
Vardenafil—Scotoma—Doxorubicin—thyroid cancer	0.00192	0.00374	CcSEcCtD
Vardenafil—Mental disorder—Sorafenib—thyroid cancer	0.00188	0.00365	CcSEcCtD
Vardenafil—Erythema—Sorafenib—thyroid cancer	0.00186	0.00363	CcSEcCtD
Vardenafil—Feeling hot—Doxorubicin—thyroid cancer	0.00186	0.00362	CcSEcCtD
Vardenafil—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00184	0.00359	CcSEcCtD
Vardenafil—Cardiovascular disorder—Epirubicin—thyroid cancer	0.00179	0.00349	CcSEcCtD
Vardenafil—Muscle spasms—Sorafenib—thyroid cancer	0.00179	0.00349	CcSEcCtD
Vardenafil—Abdominal pain—Vandetanib—thyroid cancer	0.00178	0.00347	CcSEcCtD
Vardenafil—Lacrimation increased—Epirubicin—thyroid cancer	0.00171	0.00333	CcSEcCtD
Vardenafil—Angioedema—Sorafenib—thyroid cancer	0.0017	0.00332	CcSEcCtD
Vardenafil—Syncope—Sorafenib—thyroid cancer	0.00167	0.00326	CcSEcCtD
Vardenafil—Cardiovascular disorder—Doxorubicin—thyroid cancer	0.00166	0.00323	CcSEcCtD
Vardenafil—Creatinine increased—Epirubicin—thyroid cancer	0.00165	0.00322	CcSEcCtD
Vardenafil—Loss of consciousness—Sorafenib—thyroid cancer	0.00164	0.00319	CcSEcCtD
Vardenafil—Asthenia—Vandetanib—thyroid cancer	0.00162	0.00315	CcSEcCtD
Vardenafil—Pruritus—Vandetanib—thyroid cancer	0.0016	0.00311	CcSEcCtD
Vardenafil—Neck pain—Epirubicin—thyroid cancer	0.00159	0.00311	CcSEcCtD
Vardenafil—Arthralgia—Sorafenib—thyroid cancer	0.00159	0.00309	CcSEcCtD
Vardenafil—Myalgia—Sorafenib—thyroid cancer	0.00159	0.00309	CcSEcCtD
Vardenafil—Lacrimation increased—Doxorubicin—thyroid cancer	0.00158	0.00308	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00158	0.00307	CcSEcCtD
Vardenafil—Dry mouth—Sorafenib—thyroid cancer	0.00155	0.00302	CcSEcCtD
Vardenafil—Diarrhoea—Vandetanib—thyroid cancer	0.00154	0.00301	CcSEcCtD
Vardenafil—Creatinine increased—Doxorubicin—thyroid cancer	0.00153	0.00298	CcSEcCtD
Vardenafil—Influenza like illness—Epirubicin—thyroid cancer	0.00153	0.00298	CcSEcCtD
Vardenafil—Anaphylactic shock—Sorafenib—thyroid cancer	0.00152	0.00296	CcSEcCtD
Vardenafil—Infection—Sorafenib—thyroid cancer	0.00151	0.00294	CcSEcCtD
Vardenafil—Shock—Sorafenib—thyroid cancer	0.0015	0.00291	CcSEcCtD
Vardenafil—Nervous system disorder—Sorafenib—thyroid cancer	0.00149	0.00291	CcSEcCtD
Vardenafil—Dizziness—Vandetanib—thyroid cancer	0.00149	0.0029	CcSEcCtD
Vardenafil—Skin disorder—Sorafenib—thyroid cancer	0.00148	0.00288	CcSEcCtD
Vardenafil—Neck pain—Doxorubicin—thyroid cancer	0.00148	0.00287	CcSEcCtD
Vardenafil—Oesophagitis—Epirubicin—thyroid cancer	0.00144	0.0028	CcSEcCtD
Vardenafil—Vomiting—Vandetanib—thyroid cancer	0.00143	0.00279	CcSEcCtD
Vardenafil—Rash—Vandetanib—thyroid cancer	0.00142	0.00277	CcSEcCtD
Vardenafil—Dermatitis—Vandetanib—thyroid cancer	0.00142	0.00277	CcSEcCtD
Vardenafil—Influenza like illness—Doxorubicin—thyroid cancer	0.00142	0.00276	CcSEcCtD
Vardenafil—Headache—Vandetanib—thyroid cancer	0.00141	0.00275	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00139	0.0027	CcSEcCtD
Vardenafil—Hypertonia—Epirubicin—thyroid cancer	0.00138	0.00269	CcSEcCtD
Vardenafil—Abnormal vision—Epirubicin—thyroid cancer	0.00137	0.00268	CcSEcCtD
Vardenafil—Dyspnoea—Sorafenib—thyroid cancer	0.00136	0.00264	CcSEcCtD
Vardenafil—Nausea—Vandetanib—thyroid cancer	0.00134	0.00261	CcSEcCtD
Vardenafil—Dyspepsia—Sorafenib—thyroid cancer	0.00134	0.00261	CcSEcCtD
Vardenafil—Oesophagitis—Doxorubicin—thyroid cancer	0.00133	0.00259	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00131	0.00256	CcSEcCtD
Vardenafil—Pain—Sorafenib—thyroid cancer	0.0013	0.00253	CcSEcCtD
Vardenafil—Hypertonia—Doxorubicin—thyroid cancer	0.00128	0.00249	CcSEcCtD
Vardenafil—Abnormal vision—Doxorubicin—thyroid cancer	0.00127	0.00248	CcSEcCtD
Vardenafil—Eye pain—Epirubicin—thyroid cancer	0.00127	0.00247	CcSEcCtD
Vardenafil—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00124	0.00242	CcSEcCtD
Vardenafil—Hot flush—Epirubicin—thyroid cancer	0.00122	0.00238	CcSEcCtD
Vardenafil—Menopausal symptoms—Epirubicin—thyroid cancer	0.00121	0.00236	CcSEcCtD
Vardenafil—Abdominal pain—Sorafenib—thyroid cancer	0.0012	0.00234	CcSEcCtD
Vardenafil—Eye pain—Doxorubicin—thyroid cancer	0.00117	0.00228	CcSEcCtD
Vardenafil—Hot flush—Doxorubicin—thyroid cancer	0.00113	0.0022	CcSEcCtD
Vardenafil—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00112	0.00218	CcSEcCtD
Vardenafil—Hypersensitivity—Sorafenib—thyroid cancer	0.00112	0.00218	CcSEcCtD
Vardenafil—Face oedema—Epirubicin—thyroid cancer	0.0011	0.00215	CcSEcCtD
Vardenafil—Asthenia—Sorafenib—thyroid cancer	0.00109	0.00213	CcSEcCtD
Vardenafil—Pruritus—Sorafenib—thyroid cancer	0.00108	0.0021	CcSEcCtD
Vardenafil—Blood creatinine increased—Epirubicin—thyroid cancer	0.00107	0.00209	CcSEcCtD
Vardenafil—Liver function test abnormal—Epirubicin—thyroid cancer	0.00106	0.00206	CcSEcCtD
Vardenafil—Abdominal pain upper—Epirubicin—thyroid cancer	0.00104	0.00203	CcSEcCtD
Vardenafil—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00104	0.00203	CcSEcCtD
Vardenafil—Diarrhoea—Sorafenib—thyroid cancer	0.00104	0.00203	CcSEcCtD
Vardenafil—Breast disorder—Epirubicin—thyroid cancer	0.00103	0.00201	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00103	0.00201	CcSEcCtD
Vardenafil—Face oedema—Doxorubicin—thyroid cancer	0.00102	0.00199	CcSEcCtD
Vardenafil—Gastritis—Epirubicin—thyroid cancer	0.00101	0.00197	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00101	0.00196	CcSEcCtD
Vardenafil—Dizziness—Sorafenib—thyroid cancer	0.00101	0.00196	CcSEcCtD
Vardenafil—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000991	0.00193	CcSEcCtD
Vardenafil—Dysphagia—Epirubicin—thyroid cancer	0.000988	0.00193	CcSEcCtD
Vardenafil—Influenza—Epirubicin—thyroid cancer	0.000988	0.00193	CcSEcCtD
Vardenafil—Liver function test abnormal—Doxorubicin—thyroid cancer	0.000977	0.0019	CcSEcCtD
Vardenafil—Vomiting—Sorafenib—thyroid cancer	0.000967	0.00188	CcSEcCtD
Vardenafil—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000966	0.00188	CcSEcCtD
Vardenafil—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000966	0.00188	CcSEcCtD
Vardenafil—Angina pectoris—Epirubicin—thyroid cancer	0.000963	0.00188	CcSEcCtD
Vardenafil—Rash—Sorafenib—thyroid cancer	0.000959	0.00187	CcSEcCtD
Vardenafil—Dermatitis—Sorafenib—thyroid cancer	0.000958	0.00187	CcSEcCtD
Vardenafil—Breast disorder—Doxorubicin—thyroid cancer	0.000956	0.00186	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000953	0.00186	CcSEcCtD
Vardenafil—Headache—Sorafenib—thyroid cancer	0.000953	0.00186	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—thyroid cancer	0.000936	0.00182	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000933	0.00182	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—thyroid cancer	0.000915	0.00178	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—thyroid cancer	0.000915	0.00178	CcSEcCtD
Vardenafil—Nausea—Sorafenib—thyroid cancer	0.000903	0.00176	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000902	0.00176	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—thyroid cancer	0.000891	0.00174	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—thyroid cancer	0.000881	0.00172	CcSEcCtD
Vardenafil—Infestation—Epirubicin—thyroid cancer	0.000881	0.00172	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—thyroid cancer	0.000857	0.00167	CcSEcCtD
Vardenafil—Sweating—Epirubicin—thyroid cancer	0.000845	0.00165	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—thyroid cancer	0.00084	0.00164	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000835	0.00163	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000833	0.00162	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—thyroid cancer	0.000831	0.00162	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—thyroid cancer	0.000827	0.00161	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—thyroid cancer	0.000815	0.00159	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—thyroid cancer	0.000815	0.00159	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—thyroid cancer	0.000795	0.00155	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—thyroid cancer	0.000793	0.00155	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—thyroid cancer	0.000793	0.00154	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—thyroid cancer	0.000791	0.00154	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—thyroid cancer	0.000787	0.00153	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—thyroid cancer	0.000785	0.00153	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—thyroid cancer	0.000782	0.00152	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—thyroid cancer	0.000781	0.00152	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—thyroid cancer	0.000777	0.00151	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—thyroid cancer	0.000777	0.00151	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—thyroid cancer	0.000775	0.00151	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.000771	0.0015	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—thyroid cancer	0.000769	0.0015	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—thyroid cancer	0.000765	0.00149	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—thyroid cancer	0.000762	0.00149	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—thyroid cancer	0.000739	0.00144	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—thyroid cancer	0.000738	0.00144	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—thyroid cancer	0.000736	0.00143	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—thyroid cancer	0.000734	0.00143	CcSEcCtD
Vardenafil—Flushing—Epirubicin—thyroid cancer	0.000734	0.00143	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—thyroid cancer	0.000734	0.00143	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—thyroid cancer	0.000732	0.00143	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000728	0.00142	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—thyroid cancer	0.000727	0.00142	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000723	0.00141	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000719	0.0014	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—thyroid cancer	0.000718	0.0014	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—thyroid cancer	0.000718	0.0014	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—thyroid cancer	0.000715	0.00139	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—thyroid cancer	0.000713	0.00139	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—thyroid cancer	0.000705	0.00137	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—thyroid cancer	0.000693	0.00135	CcSEcCtD
Vardenafil—Erythema—Epirubicin—thyroid cancer	0.000689	0.00134	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—thyroid cancer	0.000684	0.00133	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—thyroid cancer	0.000682	0.00133	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—thyroid cancer	0.000679	0.00132	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—thyroid cancer	0.000679	0.00132	CcSEcCtD
Vardenafil—Back pain—Epirubicin—thyroid cancer	0.000666	0.0013	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—thyroid cancer	0.000664	0.00129	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—thyroid cancer	0.000662	0.00129	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—thyroid cancer	0.000661	0.00129	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00066	0.00129	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—thyroid cancer	0.000649	0.00126	CcSEcCtD
Vardenafil—Mental disorder—Doxorubicin—thyroid cancer	0.000641	0.00125	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—thyroid cancer	0.000639	0.00124	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—thyroid cancer	0.000637	0.00124	CcSEcCtD
Vardenafil—Malaise—Epirubicin—thyroid cancer	0.000621	0.00121	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—thyroid cancer	0.000619	0.00121	CcSEcCtD
Vardenafil—Syncope—Epirubicin—thyroid cancer	0.000618	0.0012	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—thyroid cancer	0.000616	0.0012	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—thyroid cancer	0.000613	0.00119	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—thyroid cancer	0.000609	0.00119	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—thyroid cancer	0.000605	0.00118	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—thyroid cancer	0.000601	0.00117	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—thyroid cancer	0.000597	0.00116	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000591	0.00115	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—thyroid cancer	0.000586	0.00114	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—thyroid cancer	0.000586	0.00114	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—thyroid cancer	0.000586	0.00114	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—thyroid cancer	0.000584	0.00114	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000582	0.00113	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—thyroid cancer	0.000579	0.00113	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—thyroid cancer	0.000575	0.00112	CcSEcCtD
Vardenafil—Dry mouth—Epirubicin—thyroid cancer	0.000573	0.00112	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—thyroid cancer	0.000572	0.00112	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—thyroid cancer	0.000571	0.00111	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—thyroid cancer	0.000563	0.0011	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—thyroid cancer	0.000562	0.00109	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—thyroid cancer	0.00056	0.00109	CcSEcCtD
Vardenafil—Infection—Epirubicin—thyroid cancer	0.000558	0.00109	CcSEcCtD
Vardenafil—Shock—Epirubicin—thyroid cancer	0.000553	0.00108	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—thyroid cancer	0.000552	0.00108	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—thyroid cancer	0.000551	0.00107	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—thyroid cancer	0.000549	0.00107	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—thyroid cancer	0.000546	0.00106	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—thyroid cancer	0.000543	0.00106	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—thyroid cancer	0.000542	0.00106	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—thyroid cancer	0.000542	0.00106	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—thyroid cancer	0.000542	0.00106	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—thyroid cancer	0.000541	0.00105	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000539	0.00105	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—thyroid cancer	0.000536	0.00104	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—thyroid cancer	0.000531	0.00103	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—thyroid cancer	0.000525	0.00102	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00052	0.00101	CcSEcCtD
Vardenafil—Infection—Doxorubicin—thyroid cancer	0.000517	0.00101	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000512	0.000998	CcSEcCtD
Vardenafil—Shock—Doxorubicin—thyroid cancer	0.000512	0.000997	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—thyroid cancer	0.00051	0.000994	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—thyroid cancer	0.000508	0.00099	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—thyroid cancer	0.000508	0.000989	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—thyroid cancer	0.000505	0.000984	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—thyroid cancer	0.000505	0.000983	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000503	0.000979	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—thyroid cancer	0.000501	0.000976	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—PTEN—thyroid cancer	0.0005	0.00162	CbGpPWpGaD
Vardenafil—Somnolence—Epirubicin—thyroid cancer	0.0005	0.000973	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—PTEN—thyroid cancer	0.000498	0.00161	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PRKAR1A—thyroid cancer	0.000496	0.00161	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—PTEN—thyroid cancer	0.000495	0.0016	CbGpPWpGaD
Vardenafil—Dyspepsia—Epirubicin—thyroid cancer	0.000495	0.000964	CcSEcCtD
Vardenafil—PDE1B—DAP12 signaling—PTEN—thyroid cancer	0.000493	0.0016	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TSHR—thyroid cancer	0.000492	0.00159	CbGpPWpGaD
Vardenafil—PDE6G—Disease—CDK1—thyroid cancer	0.000488	0.00158	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TCF7L1—thyroid cancer	0.000486	0.00157	CbGpPWpGaD
Vardenafil—Hypotension—Doxorubicin—thyroid cancer	0.000486	0.000947	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000485	0.000945	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—PRKAR1A—thyroid cancer	0.000484	0.00156	CbGpPWpGaD
Vardenafil—Pain—Epirubicin—thyroid cancer	0.000481	0.000936	CcSEcCtD
Vardenafil—PDE1B—Hemostasis—IFNA2—thyroid cancer	0.000479	0.00155	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—NRAS—thyroid cancer	0.000475	0.00154	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MEN1—thyroid cancer	0.000474	0.00153	CbGpPWpGaD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000474	0.000923	CcSEcCtD
Vardenafil—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000471	0.00152	CbGpPWpGaD
Vardenafil—Insomnia—Doxorubicin—thyroid cancer	0.00047	0.000916	CcSEcCtD
Vardenafil—PDE11A—Signaling Pathways—PTCH1—thyroid cancer	0.000469	0.00152	CbGpPWpGaD
Vardenafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000468	0.00152	CbGpPWpGaD
Vardenafil—Paraesthesia—Doxorubicin—thyroid cancer	0.000467	0.00091	CcSEcCtD
Vardenafil—PDE1B—GPCR downstream signaling—TSHR—thyroid cancer	0.000464	0.0015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—PTEN—thyroid cancer	0.000464	0.0015	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—PTEN—thyroid cancer	0.000464	0.0015	CbGpPWpGaD
Vardenafil—Dyspnoea—Doxorubicin—thyroid cancer	0.000464	0.000903	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—thyroid cancer	0.000463	0.000902	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—thyroid cancer	0.000462	0.000901	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—MEN1—thyroid cancer	0.000462	0.0015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—PTEN—thyroid cancer	0.00046	0.00149	CbGpPWpGaD
Vardenafil—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00046	0.000895	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—thyroid cancer	0.000458	0.000892	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—PTEN—thyroid cancer	0.000456	0.00147	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—PTEN—thyroid cancer	0.000454	0.00147	CbGpPWpGaD
Vardenafil—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000449	0.000875	CcSEcCtD
Vardenafil—PDE1B—Signaling by NGF—BRAF—thyroid cancer	0.000449	0.00145	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—CDK1—thyroid cancer	0.000448	0.00145	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—NRAS—thyroid cancer	0.000446	0.00144	CbGpPWpGaD
Vardenafil—Pain—Doxorubicin—thyroid cancer	0.000445	0.000866	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—thyroid cancer	0.000444	0.000866	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—NRAS—thyroid cancer	0.000444	0.00144	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—NRAS—thyroid cancer	0.000442	0.00143	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—NRAS—thyroid cancer	0.00044	0.00142	CbGpPWpGaD
Vardenafil—CYP3A5—Biological oxidations—RXRA—thyroid cancer	0.000436	0.00141	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—IFNA2—thyroid cancer	0.000431	0.00139	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—SST—thyroid cancer	0.000429	0.00139	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTCH1—thyroid cancer	0.000429	0.00139	CbGpPWpGaD
Vardenafil—Feeling abnormal—Doxorubicin—thyroid cancer	0.000429	0.000835	CcSEcCtD
Vardenafil—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000425	0.000828	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—TSHR—thyroid cancer	0.000422	0.00136	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTCH1—thyroid cancer	0.000418	0.00135	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000415	0.00134	CbGpPWpGaD
Vardenafil—Hypersensitivity—Epirubicin—thyroid cancer	0.000414	0.000807	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR in disease—NRAS—thyroid cancer	0.000414	0.00134	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—NRAS—thyroid cancer	0.000414	0.00134	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CALCA—thyroid cancer	0.000413	0.00134	CbGpPWpGaD
Vardenafil—Abdominal pain—Doxorubicin—thyroid cancer	0.000411	0.000801	CcSEcCtD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—PTEN—thyroid cancer	0.000411	0.00133	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—NRAS—thyroid cancer	0.00041	0.00133	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—KRAS—thyroid cancer	0.000409	0.00132	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—NRAS—thyroid cancer	0.000407	0.00132	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—NRAS—thyroid cancer	0.000405	0.00131	CbGpPWpGaD
Vardenafil—Asthenia—Epirubicin—thyroid cancer	0.000403	0.000786	CcSEcCtD
Vardenafil—Pruritus—Epirubicin—thyroid cancer	0.000398	0.000775	CcSEcCtD
Vardenafil—PDE11A—Hemostasis—NRAS—thyroid cancer	0.000395	0.00128	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—SST—thyroid cancer	0.000392	0.00127	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRG1—thyroid cancer	0.000392	0.00127	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—TPR—thyroid cancer	0.000385	0.00125	CbGpPWpGaD
Vardenafil—Diarrhoea—Epirubicin—thyroid cancer	0.000385	0.000749	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—KRAS—thyroid cancer	0.000384	0.00124	CbGpPWpGaD
Vardenafil—Hypersensitivity—Doxorubicin—thyroid cancer	0.000383	0.000746	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—KRAS—thyroid cancer	0.000382	0.00124	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—SST—thyroid cancer	0.000382	0.00124	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—LGALS3—thyroid cancer	0.000382	0.00124	CbGpPWpGaD
Vardenafil—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000382	0.00124	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—KRAS—thyroid cancer	0.00038	0.00123	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PRKAR1A—thyroid cancer	0.000379	0.00123	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—KRAS—thyroid cancer	0.000379	0.00122	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CALCA—thyroid cancer	0.000378	0.00122	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CDK1—thyroid cancer	0.000374	0.00121	CbGpPWpGaD
Vardenafil—Asthenia—Doxorubicin—thyroid cancer	0.000373	0.000727	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—thyroid cancer	0.000372	0.000724	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—CALCA—thyroid cancer	0.000368	0.00119	CbGpPWpGaD
Vardenafil—Pruritus—Doxorubicin—thyroid cancer	0.000368	0.000717	CcSEcCtD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—NRAS—thyroid cancer	0.000367	0.00119	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—SST—thyroid cancer	0.000361	0.00117	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRG1—thyroid cancer	0.00036	0.00116	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PTCH1—thyroid cancer	0.000359	0.00116	CbGpPWpGaD
Vardenafil—Vomiting—Epirubicin—thyroid cancer	0.000357	0.000696	CcSEcCtD
Vardenafil—PDE1B—DAP12 interactions—KRAS—thyroid cancer	0.000356	0.00115	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—KRAS—thyroid cancer	0.000356	0.00115	CbGpPWpGaD
Vardenafil—Diarrhoea—Doxorubicin—thyroid cancer	0.000356	0.000693	CcSEcCtD
Vardenafil—PDE1B—Disease—TPR—thyroid cancer	0.000356	0.00115	CbGpPWpGaD
Vardenafil—Rash—Epirubicin—thyroid cancer	0.000354	0.00069	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—thyroid cancer	0.000354	0.00069	CcSEcCtD
Vardenafil—PDE1B—Signaling by EGFR—KRAS—thyroid cancer	0.000353	0.00114	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—NRAS—thyroid cancer	0.000352	0.00114	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—NRAS—thyroid cancer	0.000352	0.00114	CbGpPWpGaD
Vardenafil—Headache—Epirubicin—thyroid cancer	0.000352	0.000686	CcSEcCtD
Vardenafil—PDE6G—Disease—TERT—thyroid cancer	0.000352	0.00114	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PRKAR1A—thyroid cancer	0.00035	0.00113	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—KRAS—thyroid cancer	0.00035	0.00113	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—KRAS—thyroid cancer	0.000348	0.00113	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CALCA—thyroid cancer	0.000348	0.00112	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—HRAS—thyroid cancer	0.000347	0.00112	CbGpPWpGaD
Vardenafil—Dizziness—Doxorubicin—thyroid cancer	0.000344	0.00067	CcSEcCtD
Vardenafil—PDE6G—Signaling Pathways—CDK1—thyroid cancer	0.000342	0.00111	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TCF7L1—thyroid cancer	0.00034	0.0011	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—KRAS—thyroid cancer	0.00034	0.0011	CbGpPWpGaD
Vardenafil—PDE6G—Signaling by Wnt—AKT1—thyroid cancer	0.00034	0.0011	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HIF1A—thyroid cancer	0.000336	0.00109	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MEN1—thyroid cancer	0.000334	0.00108	CbGpPWpGaD
Vardenafil—Nausea—Epirubicin—thyroid cancer	0.000334	0.00065	CcSEcCtD
Vardenafil—PDE10A—Signaling Pathways—CDK1—thyroid cancer	0.000333	0.00108	CbGpPWpGaD
Vardenafil—Vomiting—Doxorubicin—thyroid cancer	0.000331	0.000644	CcSEcCtD
Vardenafil—PDE1B—Signaling by GPCR—SST—thyroid cancer	0.000328	0.00106	CbGpPWpGaD
Vardenafil—Rash—Doxorubicin—thyroid cancer	0.000328	0.000639	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—thyroid cancer	0.000328	0.000638	CcSEcCtD
Vardenafil—PDE1B—Downstream signal transduction—HRAS—thyroid cancer	0.000327	0.00106	CbGpPWpGaD
Vardenafil—Headache—Doxorubicin—thyroid cancer	0.000326	0.000635	CcSEcCtD
Vardenafil—PDE1B—Signaling by FGFR—HRAS—thyroid cancer	0.000325	0.00105	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—HRAS—thyroid cancer	0.000323	0.00105	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—HRAS—thyroid cancer	0.000322	0.00104	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—MINPP1—thyroid cancer	0.000321	0.00104	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—PTEN—thyroid cancer	0.000316	0.00102	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CALCA—thyroid cancer	0.000316	0.00102	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—KRAS—thyroid cancer	0.000315	0.00102	CbGpPWpGaD
Vardenafil—Nausea—Doxorubicin—thyroid cancer	0.000309	0.000602	CcSEcCtD
Vardenafil—PDE1B—Downstream signaling of activated FGFR—AKT1—thyroid cancer	0.000307	0.000993	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—KRAS—thyroid cancer	0.000303	0.000981	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—KRAS—thyroid cancer	0.000303	0.000981	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—HRAS—thyroid cancer	0.000303	0.00098	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—HRAS—thyroid cancer	0.000303	0.00098	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—TP53—thyroid cancer	0.000302	0.000979	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—HRAS—thyroid cancer	0.0003	0.000971	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRG1—thyroid cancer	0.0003	0.00097	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—HRAS—thyroid cancer	0.000297	0.000962	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—HRAS—thyroid cancer	0.000296	0.000958	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—HRAS—thyroid cancer	0.000289	0.000936	CbGpPWpGaD
Vardenafil—PDE1B—Downstream signal transduction—AKT1—thyroid cancer	0.000288	0.000933	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR—AKT1—thyroid cancer	0.000287	0.000928	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CDK1—thyroid cancer	0.000286	0.000925	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by ERBB2—AKT1—thyroid cancer	0.000286	0.000924	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 signaling—AKT1—thyroid cancer	0.000284	0.000919	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—NRAS—thyroid cancer	0.000282	0.000912	CbGpPWpGaD
Vardenafil—PDE6G—Disease—BRAF—thyroid cancer	0.000279	0.000901	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRG1—thyroid cancer	0.000274	0.000888	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—NDUFA13—thyroid cancer	0.000273	0.000882	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—TP53—thyroid cancer	0.00027	0.000872	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—TP53—thyroid cancer	0.00027	0.000872	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TERT—thyroid cancer	0.000269	0.000871	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	0.000268	0.000868	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRG1—thyroid cancer	0.000267	0.000865	CbGpPWpGaD
Vardenafil—PDE1B—DAP12 interactions—AKT1—thyroid cancer	0.000267	0.000865	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by FGFR in disease—AKT1—thyroid cancer	0.000267	0.000865	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CALCA—thyroid cancer	0.000266	0.000862	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR—AKT1—thyroid cancer	0.000265	0.000857	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by EGFR in Cancer—AKT1—thyroid cancer	0.000263	0.00085	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by PDGF—AKT1—thyroid cancer	0.000261	0.000846	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDK1—thyroid cancer	0.000261	0.000845	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—HRAS—thyroid cancer	0.000258	0.000834	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—HRAS—thyroid cancer	0.000258	0.000834	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HIF1A—thyroid cancer	0.000258	0.000833	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CHST14—thyroid cancer	0.000256	0.000829	CbGpPWpGaD
Vardenafil—PDE11A—Hemostasis—AKT1—thyroid cancer	0.000255	0.000826	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IFNA2—thyroid cancer	0.000251	0.000812	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TSHR—thyroid cancer	0.000249	0.000806	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TERT—thyroid cancer	0.000246	0.000797	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PRKAR1A—thyroid cancer	0.000245	0.000793	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—KRAS—thyroid cancer	0.000243	0.000785	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CDK1—thyroid cancer	0.000241	0.00078	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TERT—thyroid cancer	0.00024	0.000777	CbGpPWpGaD
Vardenafil—PDE1B—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	0.000237	0.000766	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HIF1A—thyroid cancer	0.000236	0.000762	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MEN1—thyroid cancer	0.000234	0.000758	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HIF1A—thyroid cancer	0.00023	0.000743	CbGpPWpGaD
Vardenafil—PDE10A—Hemostasis—AKT1—thyroid cancer	0.000228	0.000737	CbGpPWpGaD
Vardenafil—PDE5A—Hemostasis—AKT1—thyroid cancer	0.000228	0.000737	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—NRAS—thyroid cancer	0.000227	0.000734	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTGS2—thyroid cancer	0.000225	0.000728	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—BRAF—thyroid cancer	0.000213	0.00069	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTCH1—thyroid cancer	0.000212	0.000685	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRG1—thyroid cancer	0.00021	0.000678	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—HPGD—thyroid cancer	0.000207	0.000668	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—HRAS—thyroid cancer	0.000206	0.000667	CbGpPWpGaD
Vardenafil—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000203	0.000656	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—NRAS—thyroid cancer	0.000202	0.000654	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PTEN—thyroid cancer	0.000196	0.000635	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—KRAS—thyroid cancer	0.000195	0.000632	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—BRAF—thyroid cancer	0.000195	0.000631	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—SST—thyroid cancer	0.000194	0.000627	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRG1—thyroid cancer	0.000193	0.000626	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—BRAF—thyroid cancer	0.00019	0.000615	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CALCA—thyroid cancer	0.000186	0.000603	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—AKT1—thyroid cancer	0.000182	0.000589	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PTEN—thyroid cancer	0.00018	0.000583	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NRAS—thyroid cancer	0.000179	0.000578	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRAS—thyroid cancer	0.000175	0.000566	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—KRAS—thyroid cancer	0.000174	0.000563	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TERT—thyroid cancer	0.000174	0.000562	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDK1—thyroid cancer	0.000169	0.000546	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HIF1A—thyroid cancer	0.000166	0.000538	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—thyroid cancer	0.000166	0.000537	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—AKT1—thyroid cancer	0.000161	0.000522	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRAS—thyroid cancer	0.000161	0.00052	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CCND1—thyroid cancer	0.000156	0.000504	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KRAS—thyroid cancer	0.000154	0.000497	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KRAS—thyroid cancer	0.000151	0.000488	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTEN—thyroid cancer	0.00015	0.000486	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000149	0.000482	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—thyroid cancer	0.000148	0.000479	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—AKT1—thyroid cancer	0.000147	0.000474	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—AKT1—thyroid cancer	0.000144	0.000465	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCND1—thyroid cancer	0.000142	0.000461	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CCND1—thyroid cancer	0.000139	0.000449	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—thyroid cancer	0.000138	0.000448	CbGpPWpGaD
Vardenafil—PDE1B—Disease—BRAF—thyroid cancer	0.000138	0.000445	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTEN—thyroid cancer	0.000137	0.000445	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—thyroid cancer	0.000137	0.000442	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRG1—thyroid cancer	0.000135	0.000438	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—thyroid cancer	0.000134	0.000434	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTEN—thyroid cancer	0.000134	0.000433	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—thyroid cancer	0.000131	0.000423	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—AKT1—thyroid cancer	0.000131	0.000423	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—thyroid cancer	0.000128	0.000414	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.000127	0.00041	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—thyroid cancer	0.000123	0.000397	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TERT—thyroid cancer	0.000122	0.000394	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—thyroid cancer	0.000119	0.000387	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000119	0.000385	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TPR—thyroid cancer	0.000119	0.000384	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—thyroid cancer	0.000118	0.000381	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	0.000117	0.000378	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HIF1A—thyroid cancer	0.000116	0.000376	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—AKT1—thyroid cancer	0.000115	0.000373	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—thyroid cancer	0.000115	0.000373	CbGpPWpGaD
Vardenafil—PDE6G—Disease—AKT1—thyroid cancer	0.000113	0.000366	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTGS2—thyroid cancer	0.000111	0.00036	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—thyroid cancer	0.000106	0.000341	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTEN—thyroid cancer	0.000105	0.00034	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—AKT1—thyroid cancer	0.000104	0.000336	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—thyroid cancer	0.000103	0.000333	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—thyroid cancer	0.000103	0.000332	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—thyroid cancer	0.000102	0.000332	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—thyroid cancer	9.81e-05	0.000317	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTEN—thyroid cancer	9.69e-05	0.000314	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—BRAF—thyroid cancer	9.63e-05	0.000312	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—HPGD—thyroid cancer	9.6e-05	0.000311	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—thyroid cancer	9.38e-05	0.000303	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—thyroid cancer	9.37e-05	0.000303	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—thyroid cancer	9.14e-05	0.000296	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—thyroid cancer	8.97e-05	0.00029	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SLC5A5—thyroid cancer	8.88e-05	0.000287	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—thyroid cancer	8.82e-05	0.000285	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—thyroid cancer	8.74e-05	0.000283	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—AKT1—thyroid cancer	8.66e-05	0.00028	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—thyroid cancer	8.65e-05	0.00028	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—thyroid cancer	8.06e-05	0.000261	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—AKT1—thyroid cancer	7.92e-05	0.000256	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—AKT1—thyroid cancer	7.72e-05	0.00025	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—thyroid cancer	7.5e-05	0.000243	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—RXRA—thyroid cancer	7.46e-05	0.000241	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—thyroid cancer	7.44e-05	0.000241	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—AKT1—thyroid cancer	7.29e-05	0.000236	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCND1—thyroid cancer	7.03e-05	0.000227	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—thyroid cancer	6.85e-05	0.000222	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTEN—thyroid cancer	6.79e-05	0.00022	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—AKT1—thyroid cancer	6.62e-05	0.000214	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—thyroid cancer	6.33e-05	0.000205	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—thyroid cancer	6.06e-05	0.000196	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—AKT1—thyroid cancer	6.05e-05	0.000196	CbGpPWpGaD
Vardenafil—PDE1B—Disease—AKT1—thyroid cancer	5.59e-05	0.000181	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TPR—thyroid cancer	5.52e-05	0.000178	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.43e-05	0.000176	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—thyroid cancer	5.21e-05	0.000169	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PPARG—thyroid cancer	4.71e-05	0.000152	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—thyroid cancer	4.63e-05	0.00015	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—thyroid cancer	4.43e-05	0.000143	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.13e-05	0.000134	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKT1—thyroid cancer	3.91e-05	0.000127	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTGS2—thyroid cancer	3.71e-05	0.00012	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—RXRA—thyroid cancer	3.47e-05	0.000112	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTEN—thyroid cancer	3.23e-05	0.000105	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPARG—thyroid cancer	2.19e-05	7.09e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKT1—thyroid cancer	1.86e-05	6.03e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.72e-05	5.57e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTEN—thyroid cancer	1.5e-05	4.86e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKT1—thyroid cancer	8.66e-06	2.8e-05	CbGpPWpGaD
